New BIA report unveils and explains UK's leadership potential in oligonucleotide therapies
London, 24 March 2025 – The BioIndustry Association (BIA) today publishes a pioneering report, Oligos explainer: A new frontier in precision medicine, highlighting the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.
This report aims to explain the science, history, opportunity and manufacturing challenges of oligos to the non-expert audience. It introduces some of the key UK players who are at the forefront of this exciting field and explains how and why we can establish ourselves as a global industrial leader in this transformative field. With 18 therapies already approved globally—17 targeting rare diseases—and a growing focus on oncology, the oligo clinical pipeline signals a bright future.
Steve Bates OBE, CEO of the BIA, said:
The UK is well placed to capture the global economic value from being in the vanguard of this new industry. Solving manufacturing challenges is key to the successful delivery of new therapies. Our report will serve as a catalyst, amplifying awareness of the immense potential of oligonucleotide therapies and inspiring increased investment. By forging strong partnerships and fostering collaboration, we can solidify the UK's position as a premier destination for oligonucleotide research, development and manufacture.
The report features a map of oligonucleotide companies across the UK which illustrates the vibrant industry landscape. Strategic investments, such as the CPI’s Oligonucleotide Manufacturing Innovation Centre of Excellence (OMICE) and £13 million from Innovate UK to help transform medicine manufacturing and a further £4.5 million for nucleic acid medicine manufacturing, ensure the UK stands out as a global home for this emerging industry. It is bolstered by a world-class research ecosystem, a skilled workforce, and a supportive regulatory framework.
